OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

22.00USD
28 Jul 2014
Price Change (% chg)

$-0.84 (-3.68%)
Prev Close
$22.84
Open
$23.00
Day's High
$23.00
Day's Low
$21.59
Volume
47,431
Avg. Vol
42,243
52-wk High
$42.34
52-wk Low
$12.10

OMED.OQ

Chart for OMED.OQ

About

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential... (more)

Overall

Beta: --
Market Cap (Mil.): $650.22
Shares Outstanding (Mil.): 29.56
Dividend: --
Yield (%): --

Financials

  OMED.OQ Industry Sector
P/E (TTM): 3.67 103.84 36.07
EPS (TTM): 6.00 -- --
ROI: -20.80 -0.24 18.18
ROE: -- -1.24 19.05
Search Stocks

OncoMed halts enrollment in trials of two cancer drugs

- OncoMed Pharmaceuticals Inc said it halted patient enrollment and dosing in all ongoing early-stage trials of two of its experimental cancer drugs over concerns of bone damage.

13 Jun 2014

Competitors

  Price Change
Amgen, Inc. (AMGN.OQ) $122.65 -0.19
Astellas Pharma Inc (4503.T) ¥1,422 +8.00
AstraZeneca plc (AZN.L) 4,342.00p -19.00
Bayer AG (BAYGn.DE) €99.49 +0.20
Bayer AG (BAYE.F) -- --
Celgene Corporation (CELG.OQ) $87.64 +0.48
Roche Holding Ltd. (ROG.VX) CHF266.80 +1.30
GlaxoSmithKline plc (GSK.L) 1,430.93p +16.50
Johnson & Johnson (JNJ.N) $102.11 0.00
Eli Lilly and Co (LLY.N) $63.39 -0.39

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks